TEM's Q2 Turnaround Is Real. The $7.7 Billion Debate Starts Now.

Q2 profitability changes the near-term Tempus narrative

This quarter changes the setup. After Q2 revenue of $382.5 million, up 22% year over year and GAAP net income of $5.6 million, the old argument that Tempus could not execute is much harder to defend. The more important question now is whether investors rerate the stock on that proof, or treat it as one strong quarter inside a still-skeptical story.

That debate is timely because management also raised its 2026 outlook to $1.595 to $1.605 billion for 2026 and expects full year Adjusted EBITDA of ~$65 million. If the market starts paying for repeatable execution rather than distant optionality, this quarter may look like the turning point in hindsight.

Growth quality improved alongside profitability

The bull case is not just that Tempus grew; it is that growth improved in the right places. The company reported oncology volume growth of 31% year-over-year and Data Licensing & Modeling revenue up 36%. Those are the higher-value parts of the business, and they help explain why the quarter also produced adjusted EBITDA of $8.0 million.

The skeptical view is more disciplined: one profitable quarter is not the same as durable operating leverage. That makes execution consistency the key test from here, with Personalis integration becoming the latest milestone to watch.

The flywheel is the bull case; premature pricing is the bear case

Why the flywheel matters

The stronger bull case is not one good quarter. It is a self-reinforcing loop built on GAAP net income of $5.6 million, adjusted EBITDA of $8.0 million, and $820.7 million in cash and marketable securities at quarter end. Even with negative $7.5 million in operating cash use this quarter, that balance sheet gives management more flexibility, especially after the $460 million notes offering.

The logic is straightforward:

• Stronger diagnostics and data traction can fund deeper product integration.
• Broader adoption across clinics and sponsors can expand the customer base.
• A larger customer base can generate more real-world data and improve model training.
• Better data and models can support more trials, more workflows, and stronger pricing power over time.

That is why roughly $200 million in new Data and Applications licenses matters. The figures suggest customers already view Tempus as more than a one-time test vendor.

Where investors may be jumping ahead

The bear case is that investors may be pricing future convergence as if it already exists. FDA approval of xT Tumor Only does create a path to about $85 million of annual revenue beginning in 2027, and a future xF liquid-biopsy approval could bring total revenue uplift from the two products to approximately $400 million in 2028. But those are future upside drivers, not current revenue contributions.

The same caution applies to Personalis. The deal is meaningful at $1.5 billion enterprise value, and it fits Tempus' strategy because it adds tumor-informed MRD technology to the platform. Still, strategic logic should be separated from immediate earnings contribution while MRD remains commercially early.

What investors should watch next

The debate is no longer whether Tempus can post a decent quarter. It is whether the company can turn that result into repeatable growth, better economics, and cleaner integration. The clearest checkpoints are:

• Another quarter of profitable or near-profitable performance.
• Sustained growth in oncology volume and data licensing.
• Progress blending Personalis' MRD capabilities into the broader platform.
• Evidence that new license commitments translate into durable recurring revenue.

If those checkpoints arrive, the rerating case becomes less about narrative and more about a business that is beginning to compound.